Literature DB >> 15814512

Continuous morphine infusions for cancer pain in resource-scarce environments: comparison of the subcutaneous and intravenous routes of administration.

Rachel C Koshy1, Renju Kuriakose, Paul Sebastian, Cherian Koshy.   

Abstract

Acute onset of severe pain in cancer patients may be due to multiple causes. Irrespective of the etiology, adequate analgesia has to be provided as quickly as possible. The standard practices of relieving pain by using syringe pumps (syringe drivers) or infusion pumps may not be feasible in resource-scarce developing nations where many cancer patients first present at advanced stages of disease for management. This study compared the efficacy of the subcutaneous and intravenous routes of morphine administration continuously using a simple and economic technique for cancer pain management. Both routes were found to be equally effective in producing good analgesia without side effects. The drip method is a cost-effective way of providing subcutaneous morphine infusion for cancer patients and is applicable for both inpatients and home care.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814512

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  3 in total

1.  [Under what conditions is subcutaneous administration of fluid indicated].

Authors:  C Bausewein
Journal:  Internist (Berl)       Date:  2007-04       Impact factor: 0.743

2.  Intermittent subcutaneous opioids for the management of cancer pain.

Authors:  Henrique A Parsons; Abdul Shukkoor; Hue Quan; Marvin O Delgado-Guay; J Lynn Palmer; Robin Fainsinger; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-12       Impact factor: 2.947

Review 3.  Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease.

Authors:  Katharine Ker; Gavin Tansley; Deirdre Beecher; Anders Perner; Haleema Shakur; Tim Harris; Ian Roberts
Journal:  Cochrane Database Syst Rev       Date:  2015-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.